Molecular and clinical stratification of astroblastomas: Three distinct fusion-defined groups informing risk-adapted treatment strategies

Astroblastoma, MN1-altered, comprises three molecularly and clinically distinct groups, characterized by different fusion genes, including those without MN1. These new insights, including identification of potential predictive biomarkers like 14q/16q loss, provide a framework for development of risk-stratified therapeutic approaches. Importantly, we identified a molecularly defined high-risk group that benefits from radiation therapy. Our findings redefine Astroblastoma as a molecularly diverse tumor type, propose a refined classification, support the development of risk-adapted therapeutic strategies and provide a rational standard of care.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-12-18
DOI
https://doi.org/10.1093/neuonc/noaf283
Citations
2
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
3.25
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Molecular and clinical stratification of astroblastomas: Three distinct fusion-defined groups informing risk-adapted treatment strategies

Vijay Ramaswamy, Aditya Raghunathan, R. Packer, Christof M. Kramm et al.
2 citations
Neuro-Oncology
Glioma Diagnosis and Treatment
3.25
article

Molecular and clinical stratification of astroblastomas: Three distinct fusion-defined groups informing risk-adapted treatment strategies

Vijay Ramaswamy, Aditya Raghunathan, R. Packer, Christof M. Kramm, Lorena Baroni, Adriana Fonseca, Barbara Aistleitner, Jens Bunt, Yelena Wilson, Jordan R. Hansford, Martin Sill, Daniel Schrimpf, Johannes Gojo, Felix Schmitt-Hoffner, Mariëtte E.G. Kranendonk, Lauren Weintraub, Stefan M. Pfister, Zied Abdullaev, Katharina Bruckner, Andreas von Deimling, Natalie Jäger, J. Koster, Maria Łastowska, Andrew M. Donson, Florian Selt, Pascale Varlet, Jasper van der Lugt, Dominik Sturm, M. Kool, Monika Mauermann, Aniello Federico, Damian Stichel, Evelina Miele, Christine Haberler, Ulrich Schüller, Barbara C. Jones, Prof Felix Sahm, Sabine Spiegl-Kreinecker, Mimi Kjaersgaard, Manila Antonelli, Kenneth Aldape, Neal Geisemeyer, Arnault Tauziede-Espariat, Katja Von Hoff, Matija Snuderl, David Capper, Lane Williamson, Michal Zapotocky, Andrey Korshunov, Sebastian Brandner, Alexandra Kolenova
article en
2 citations

Abstract

Astroblastoma, MN1-altered, comprises three molecularly and clinically distinct groups, characterized by different fusion genes, including those without MN1. These new insights, including identification of potential predictive biomarkers like 14q/16q loss, provide a framework for development of risk-stratified therapeutic approaches. Importantly, we identified a molecularly defined high-risk group that benefits from radiation therapy. Our findings redefine Astroblastoma as a molecularly diverse tumor type, propose a refined classification, support the development of risk-adapted therapeutic strategies and provide a rational standard of care.

Neuro-Oncology
Johannes Kepler University of Linz (AT), Royal Children's Hospital (AU), Mayo Clinic (US), Children's National (US), Universität Hamburg (DE), German Cancer Research Center (DE), Utrecht University (NL), Charles University (CZ), Heidelberg University (DE), Garrahan Hospital (AR), Women's and Children's Hospital (AU), Hospital for Sick Children (CA), University Hospital Heidelberg (DE), Aarhus University Hospital (DK), Rigshospitalet (DK), Istituto Neurologico Mediterraneo (IT), University Medical Center Utrecht (NL), Humboldt-Universität zu Berlin (DE), Comprehensive Cancer Center Vienna (AT), Morgan Adams Foundation (US), University Hospital in Motol (CZ), Akron Children's Hospital (US), Amsterdam Neuroscience (NL), University Medical Center Hamburg-Eppendorf (DE), Kinderkrebs-Zentrum Hamburg (DE), National Center for Tumor Diseases (DE), Children's Memorial Health Institute (PL), Hopp Children's Cancer Center Heidelberg (DE), Nephrologisches Zentrum Goettingen (DE), Kepler Universitätsklinikum (AT), Bambino Gesù Children's Hospital (IT), Centre Hospitalier Sainte-Anne (FR), Mayo Clinic in Arizona (US), Princess Máxima Center (NL), South Australian Health and Medical Research Institute (AU), Centre for Cancer Biology (AU), National Cancer Institute (US), Deutsches Konsortium für Translationale Krebsforschung (DE), University College London (GB), New York University (US), Comenius University Bratislava (SK), Medical University of Vienna (AT), Albany Medical Center Hospital (US), Charité - Universitätsmedizin Berlin (DE), Heidelberg University (US), Sapienza University of Rome (IT), University of Amsterdam (NL)
No poverty
Openalex Percentile: Top 7%
Glioma Diagnosis and Treatment
3.25
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.